Sagent Pharmaceuticals Launches Vecuronium Bromide For Injection
SCHAUMBURG, Ill., Aug. 18, 2011 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of vecuronium bromide for injection, a neuromuscular blocking agent, in 10 and 20 mg single-use vials. According to 2010 IMS data, the U.S. vecuronium bromide market approximated $10 million. As with all products in Sagent's portfolio, vecuronium bromide for injection features the company's PreventIV Measures packaging and labeling designed to aid in the reduction of medication errors.
"Vecuronium bromide is currently in short supply in the United States and we are pleased to offer our customers a source for this important niche product," said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent.
About Vecuronium Bromide for Injection
In patients who are known to have myasthenia gravis or the myasthenic (Eaton-Lambert) syndrome (muscle weakness/fatigue), small doses of vecuronium may have been found to be effective. In such patients, a peripheral nerve stimulator and use of a small test dose may be of value in monitoring the response to administration of muscle relaxants.
The package insert, which is available at www.SagentPharma.com, contains detailed information about the indications, complete side effect profile, boxed warnings and prescribing information.
About Sagent Pharmaceuticals
Sagent Pharmaceuticals, Inc., founded in 2006, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients.
Statements contained in this press release contain forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical fact, including but not limited to our expected gross margin percentage, included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give Sagent's current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business as of the date of this release. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as "anticipate," "estimate," "expect," "project," "plan," "intend," "believe," "may," "will," "should," "can have," "likely" and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. Sagent's expectations are not predictions of future performance, and future results may substantially differ from current expectations based upon a variety of factors, risks and uncertainties affecting Sagent's business, including, among others, the difficulty of predicting the timing or outcome of product development efforts and FDA approvals; the difficulty of predicting the timing and outcome of any pending litigation including litigation involving third parties that may have an impact on the timing of Sagent's product launches; the impact of competitive products and pricing and actions by Sagent's competitors with respect thereto; the timing of product launches; compliance with FDA and other governmental regulations by Sagent and its third party manufacturers; changes in laws and regulations; and such other risks detailed in Sagent's periodic public filings with the Securities and Exchange Commission, including but not limited to Sagent's most recent quarterly report on Form 10-Q and Sagent's IPO prospectus filed on April 21, 2011. Sagent disclaims and does not undertake any obligation to update or revise any forward-looking statement in this press release, except as required by applicable law or regulation.
CONTACT: SAGENT CONTACT:
Geoff Curtis, WCG
(312) 646-6298Source: Sagent Pharmaceuticals, Inc.
News Provided by Acquire Media